Pfizer Q1 FY27 net profit at Rs 204 cr, revenue up 8% YoY

Exceptional ItemResults View source PDF Explain this filing

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹4710.00

prior close

₹4716.40

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.5%+0.8% vs market

Pharmaceuticals peers, median of 165sector-0.8%+1.1% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+0.7

15m

-0.1

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.5+0.8-0.8+1.1

Next day

+1.1+0.9+0.2+0.2+0.8

+1.9+0.1+1.8-0.7+2.6

+2.4+0.5+1.9-0.3+2.7

+4.1+1.9+2.1+0.3+3.8

+3.0+2.1+0.9+0.7+2.3

+4.1+3.0+1.1+0.3+3.8

15d

+2.4+2.9-0.5+1.0+1.5

-0.2+3.8-3.9+1.6-1.7

-15.6+0.2-15.8+2.4-18.0

-20.8-4.7-16.2-2.0-18.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pfizer reported Q1 FY27 revenue from operations of Rs 653.17 crore, up 8.3% YoY from Rs 603.05 crore. Net profit rose 6.6% to Rs 204.47 crore from Rs 191.75 crore. Total income stood at Rs 698.01 crore. EPS came in at Rs 44.69 vs Rs 41.91 YoY. No exceptional items this quarter against Rs 49.16 crore in FY26 (linked to Cipla supply deal costs and new labour codes). Statutory auditor B S R and Co. LLP issued an unmodified limited review report.

Likely market impact

Steady single-digit growth in revenue and profit, clean audit, no near-term red flags. Reassuring start to the year for shareholders.